Oda Keiko, Ishikawa Eiji, Ito Takayasu, Mizoguchi Shoko, Hirabayashi Yosuke, Suzuki Yasuo, Haruki Ayumi, Fujimoto Mika, Murata Tomohiro, Katayama Kan, Onishi Takahiro, Ito Masaaki
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Japan.
Department of Nephrology, Ise Red Cross Hospital, Japan.
Intern Med. 2018 Nov 15;57(22):3267-3270. doi: 10.2169/internalmedicine.0936-18. Epub 2018 Jul 6.
Rituximab (RTX) has become a therapeutic option for inducing remission of anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). However, the optimum dosage of RTX to induce remission of AAV and reduce adverse events, such as infection, remains unclear. We herein report an elderly and renally impaired patient with alveolar hemorrhaging due to refractory AAV who was successfully treated with single infusion of RTX. Single infusion of RTX may be a therapeutic option in refractory AAV patients who are vulnerable to infections.
利妥昔单抗（RTX）已成为诱导抗中性粒细胞胞浆自身抗体相关性血管炎（AAV）缓解的一种治疗选择。然而，诱导AAV缓解并减少诸如感染等不良事件的RTX最佳剂量仍不明确。我们在此报告一例因难治性AAV导致肺泡出血的老年肾功能受损患者，该患者单次输注RTX后成功治愈。对于易发生感染的难治性AAV患者，单次输注RTX可能是一种治疗选择。
